Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging

Drug transit through the blood-brain barrier (BBB) is essential for therapeutic responses in malignant glioma. Conventional methods for assessment of BBB penetrance require synthesis of isotopically labeled drug derivatives. Here, we report a new methodology using matrix assisted laser desorption ionization mass spectrometry imaging (MALDI MSI) to visualize drug penetration in brain tissue without molecular labeling. In studies summarized here, we first validate heme as a simple and robust MALDI MSI marker for the lumen of blood vessels in the brain. We go on to provide three examples of how MALDI MSI can provide chemical and biological insights into BBB penetrance and metabolism of small molecule signal transduction inhibitors in the brain – insights that would be difficult or impossible to extract by use of radiolabeled compounds.

[1]  W. Löscher,et al.  The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses , 2007, Clinical Cancer Research.

[2]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[3]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[4]  G. V. Van Berkel,et al.  Comparison of drug distribution images from whole-body thin tissue sections obtained using desorption electrospray ionization tandem mass spectrometry and autoradiography. , 2008, Analytical chemistry.

[5]  Stevan W. Djuric,et al.  F1000Prime recommendation of Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010 .

[6]  S. Liddelow,et al.  Transporters of the blood-brain and blood-CSF interfaces in development and in the adult. , 2013, Molecular aspects of medicine.

[7]  Thomas Ludwig,et al.  Glioblastoma cells release factors that disrupt blood-brain barrier features , 2004, Acta Neuropathologica.

[8]  Francesco Hofmann,et al.  PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. , 2010, Neuro-oncology.

[9]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[10]  L. Signor,et al.  Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry. , 2007, Journal of mass spectrometry : JMS.

[11]  C. García-echeverría Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways , 2008, Purinergic Signalling.

[12]  Alain Schweitzer,et al.  Autoradiography, MALDI-MS, and SIMS-MS Imaging in Pharmaceutical Discovery and Development , 2010, The AAPS Journal.

[13]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[14]  P. Jeffrey,et al.  Assessment of the blood–brain barrier in CNS drug discovery , 2010, Neurobiology of Disease.

[15]  J. Panetta,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 , 2007, Clinical Cancer Research.

[16]  Alfred L. Nuttall,et al.  Techniques for the observation and measurement of red blood cell velocity in vessels of the guinea pig cochlea , 1987, Hearing Research.

[17]  G. Reifenberger,et al.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. , 2008, The Journal of clinical investigation.

[18]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[19]  M. Chamberlain Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability , 2010, Expert review of neurotherapeutics.

[20]  K. Wong,et al.  Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. , 2009, Recent patents on anti-cancer drug discovery.

[21]  J. Dufour,et al.  PI(3)K/PTEN/AKT pathway. , 2011, Journal of hepatology.

[22]  Mitsutoshi Setou,et al.  Imaging Mass Spectrometry for Visualization of Drug and Endogenous Metabolite Distribution: Toward In Situ Pharmacometabolomes , 2010, Journal of Neuroimmune Pharmacology.

[23]  P. Caravatti,et al.  The ‘infinity cell’: A new trapped‐ion cell with radiofrequency covered trapping electrodes for fourier transform ion cyclotron resonance mass spectrometry , 1991 .

[24]  F. Loop,et al.  Cerebral microembolism during cardiopulmonary bypass. Retinal microvascular studies in vivo with fluorescein angiography. , 1988, The Journal of thoracic and cardiovascular surgery.

[25]  W. Sellers,et al.  Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.

[26]  N. M. Karabacak,et al.  Transformative effects of higher magnetic field in Fourier transform ion cyclotron resonance mass spectrometry , 2010, Journal of the American Society for Mass Spectrometry.

[27]  Marketa Zvelebil,et al.  Phosphoinositide 3-kinase signalling--which way to target? , 2003, Trends in pharmacological sciences.

[28]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[29]  Pengyu Hong,et al.  A hierarchical algorithm for calculating the isotopic fine structures of molecules , 2008, Journal of the American Society for Mass Spectrometry.

[30]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[31]  Mehrdad Hamidi,et al.  Brain drug targeting: a computational approach for overcoming blood-brain barrier. , 2009, Drug discovery today.

[32]  C. Prakash,et al.  METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS , 2006, Drug Metabolism and Disposition.

[33]  Masami Niwa,et al.  Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology , 2005, Cellular and Molecular Neurobiology.

[34]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[35]  Brendan Prideaux,et al.  High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. , 2011, Analytical chemistry.

[36]  Ming-Sound Tsao,et al.  A review of erlotinib and its clinical use , 2006, Expert opinion on pharmacotherapy.

[37]  E. Solon,et al.  Whole-body autoradiography in drug discovery. , 2002, Current drug metabolism.

[38]  R. McLendon,et al.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas. , 1997, Cancer research.